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Clostridium difficile is the leading cause of hospital-acquired diarrhea. Oncology patients are a 
group of immunosuppressed patients who are at increased risk for C. difficile infection. The primary 
objective of this study was to describe the demographic factors, medical history, and clinical 
characteristics and identify risk factors for C. difficile infection among oncology patients. A 
retrospective chart review was conducted for this case-control study. Seventy-seven cases were 
compared to two control groups; one control group of patients with diarrhea but whose stool samples 
were tested and were negative for C. difficile (n=77), and a second control group of patients matched to 
cases based on hospital ward and date of discharge (n=152). Multivariate analyses were performed using 
logistic regression. Adjusting for all other variables, days of hospitalization prior to test (OR=1.075, 95% 
CI 1.027, 1.124), fever on test date (OR=5.232, 95% CI 1.460, 18.755), history of C. difficile 
(OR=32.433, 95% CI 3.513, 299.445), and hypotension on test date (OR=9.245, 95% CI 1.232, 69.183) 
were significantly associated with C. difficile infection in cases compared to the negative test control 
group. When cases were compared to the matched control group, age (OR=1.042, 95% CI 1.006, 1.079), 
history of any co-infection (OR=5.614, 95% CI 1.878, 16.787), blood transfusion (OR=3.200, 95% CI 
1.251, 8.183), prior receipt of cephalosporins (OR=4.214, 95% CI 1.371, 12.952) or metronidazole 
(OR=16.005, 95% CI 3.958, 64.713), chemotherapy (OR=5.069, 95% CI 1.609, 15.972), history of C. 
difficile (OR=27.806, 95% CI 2.484, 311.290), and use of a nasogastric tube (OR=6.988, 95% CI 1.339, 
36.477) were significantly associated with C. difficile infection. Risk factors for C. difficile infection 
differed when comparing cases to the negative test control group and to the matched control group; 
however, prior history of C. difficile was a common risk factor. Based on the analysis of the matched 
control group, reduction in cephalosporin and metronidazole use, particularly among patients with a 
history of C. difficile infection, recent chemotherapy or blood transfusions, or presence of a nasogastric 




 Clostridium difficile is a gram-positive, anaerobic bacterium that is the leading cause of 
hospital-acquired diarrhea [1]. C. difficile has a wide variety of clinical presentations, ranging from 
asymptomatic carriage to mild self-limited diarrhea, pseudomembranous colitis, toxic megacolon 
perforation, and sepsis [2]. Since 2002, there has been a consistent rise in the rates of C. difficile in 
Canada, the United States, and Europe. In 2011, over 450,000 incident cases of C. difficile and 
29,000 deaths were estimated to have occurred in the United States [3]. This is a significant increase 
in the number of C. difficile cases in just five years. In 2006, United States hospitals reported a C. 
difficile diagnosis discharge rate of 300,000 cases per year, a doubling of cases since 2000 [4]. Thus, 
C. difficile cases have been steadily increasing over the recent decades, which represent significant 
patient mortality and morbidity nationwide. This increase in the number of C. difficile cases has 
been attributed to a newly identified strain, C. difficile BI/NAP1/027, which may be more virulent 
than previous strains [4]. There have been other changes in the epidemiology of C. difficile in recent 
years that exacerbate its economic and health consequences. Currently, C. difficile-associated 
disease is estimated to incur costs of up to $4.8 billion per year [2, 3].  
C. difficile has the ability to form spores, which contributes to transmission due to 
environmental contamination, particularly in healthcare settings. The spores are able to persist on 
environmental surfaces for up to several months [5]. The spores are heat and alcohol resistant, and 
contamination of surfaces often remains after cleaning and disinfection with standard disinfectants 
[6, 7]. Environmental transmission contributes to the exogenous acquisition of C. difficile which 
occurs through the fecal-oral transmission of spores. In hospital or healthcare settings, transmission 
through contact with contaminated residual spores present on healthcare professionals’ hands and 
clothing is common [5]. Acquisition of C. difficile can also be endogenous as well. Antibiotic use 
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results in the disruption of normal colonic flora which facilitates the proliferation of C. difficile and 
subsequent illness when toxigenic strains proliferate [6].  
More than 90% of C. difficile infections have been shown to occur either during or after 
antibiotic treatment, likely as a result of the disruption of the normal microbiota [5]. However, host 
factors also play a role in the development of illness. Even if a toxigenic strain is acquired, illness 
may not result if the host is able to mount an IgG antibody response, which would result in 
asymptomatic colonization. Asymptomatic colonization with C. difficile also occurs if a non-
toxigenic strain is acquired [4]. It has been estimated that 3% of the general, healthy population is 
asymptomatically colonized with C. difficile, but carriage rates are higher in patients who have been 
previously hospitalized or have received antibiotics [5]. 
 Pathogenicity of C. difficile is attributable to two main endotoxins, toxin A and toxin B. 
Non-toxigenic strains of C. difficile are generally not pathogenic [8].  In most cases, both toxins A 
and B are produced during C. difficile infection [9]. Once C. difficile proliferates and is endocytosed 
in the colon, toxins A and B induce fluid secretion, inflammation, and mucosal damage [5]. Cell 
death results from the production of tumor necrosis factor-alpha and pro-inflammatory interleukins. 
The combined tissue damage results in diarrhea or pseudomembranous colitis [5, 8]. Typical 
treatment for first occurrence of mild to moderate C. difficile is metronidazole. Oral vancomycin is 
recommended for more severe infections and for second or later recurrent episodes. Severely ill 
patients are typically identified as such if they present with leukocytosis, elevated creatinine levels, 
elevated lactate levels, hypotension, shock, ileus, colonic perforation, or megacolon, and a 
colectomy may be necessary for these patients [6]. Recently, fecal microbiota transplant has also 
been suggested as a possible treatment for C. difficile, particularly for patients with recurrent C. 
difficile infection and antimicrobial treatment failure. Fecal microbiota transplantation involves the 
infusion of healthy donor feces in the patient in order to restore the intestinal microbiota, and thus, 
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prevent C. difficile colonization. Fecal microbiota transplantation has been shown to have a very 
high efficacy, with no further recurrence of C. difficile seen in 92% of treated cases [10, 11]. 
However, further research into fecal microbiota transplantation is needed as there have been limited 
controlled studies to elucidate the benefits and potential adverse effects of this treatment.  
 There are many risk factors for C. difficile infection. A systematic review found consistent 
evidence that increasing age, severity of underlying diseases, non-surgical gastrointestinal 
procedures, nasogastric tubes, anti-ulcer medications, increasing duration of hospital stay, 
increasing duration of antibiotic course, and the use of multiple antibiotics are associated with 
increased risk of C. difficile infection [12]. However, older age and severity of underlying illnesses 
may have a confounding association with risk of C. difficile infection, as older patients and patients 
with more severe illnesses are more likely to have an increased length of hospital stay and 
subsequently, increased potential exposure to C. difficile [13]. Among antibiotics, broad-spectrum 
antibiotics – in particular, cephalosporins, clindamycin, and fluoroquinoloes – as well as penicillin 
have been the most frequently associated with increased risk of C. difficile infection. A proposed 
mechanism has been that these particular antibiotics or antibiotics classes have a large disruptive 
impact on the normal intestinal flora, and thus, facilitate colonization of toxigenic C. difficile strains 
[5, 13]. Gastrointestinal stimulants, stool softeners, and enemas have also been associated with 
increased risk of C. difficile-associated diarrhea for the similar proposed mechanism of the 
disruption of the normal intestinal flora [13]. 
 Immunosuppression is another risk factor for C. difficile infection and has been associated 
with severe C. difficile-associated illness. One study showed that patients who had been 
immunosuppressed due to medications such as corticosteroids and chemotherapeutic drugs or due to 
underlying conditions such as hematologic malignancies, HIV, and other autoimmune disorders 
were at higher risk of developing severe C. difficile infection resulting in fulminant colitis, 
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colectomy, or death [14]. Of the immunosuppressed patients, patients who had received lung 
transplants were particularly susceptible to developing fulminant C. difficile colitis [14]. Kidney-
pancreas transplant recipients have also been shown to have a high incidence of C. difficile colitis 
[15]. Another single hospital-based study also found higher rates of infections in the nephrology, 
hematology, and organ transplantation wards compared to other wards, corroborating studies that 
suggest transplant recipients may be more susceptible to C. difficile infections due to their 
immunosuppressed state [16].  
 Cancer patients are another group of immunosuppressed individuals susceptible to C. 
difficile infection. A case report implicated chemotherapeutic agents as a risk factor for C. difficile 
infection, independent of previous antibiotic exposure [17]. A review of published cases of C. 
difficile infection in patients who have received chemotherapeutic agents reported on various 
classes of chemotherapeutic agents associated with C. difficile colitis. Methotrexate was the most 
commonly received chemotherapeutic drug among patients who developed C. difficile, followed by 
doxorubicin and cyclophosphamide, and then fluorouracil. There were no significant associations 
among C. difficile infection and type of cancer [18]. Although the pathogenesis of chemotherapeutic 
agents in facilitating C. difficile infections is yet unclear, chemotherapeutic agents have been known 
to cause extensive inflammatory damages in the bowel and alter the normal gut flora. Many 
chemotherapeutic agents cause desquamation and necrosis, which may result in an adequate 
anaerobic environment for the proliferation of C. difficile [18]. In an outpatient case-control study 
that examined risk factors for C. difficile infections among cancer patients, no significant 
association between any chemotherapy or treatment and the development of C. difficile was found. 
The only significant associations found in this study were exposure to clindamycin and third-
generation cephalosporins and recent prolonged hospitalization [19]. Another case-control study 
examined risk factors for C. difficile during an outbreak in an oncology unit. Compared to patients 
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in the unit with diarrhea but negative for C. difficile, patients with C. difficile infection were more 
likely to have received chemotherapy. Receipt of both chemotherapy and exposure to antibiotics 
increased the risk of C. difficile infection [20]. 
Although studies have shown that C. difficile has been associated with significant mortality 
and morbidity and that there are many risk factors for C. difficile infection, there have been limited 
studies examining C. difficile in cancer patients. Incidences of C. difficile in cancer patients have 
previously been published as case reports, but there have been few comprehensive studies 
examining risk factors among cancer patients. Additionally, current research has been limited in 
showing consistent associations between specific chemotherapeutic drugs, other types of cancer 
treatments, types of cancers, and specific antibiotics with C. difficile infections in cancer patients. 
This study will address this gap in the current literature and aim to identify risk factors associated 
with C. difficile infections in cancer patients by assessing various demographic and clinical 
variables as well as previous medical history including prior antibiotic use and types of cancer 




Study design and subjects 
The study utilized a retrospective medical records review. Medical records of patients over 
the age of 18 years admitted to the oncology wards at Yale-New Haven Hospital between February 
1, 2013 and June 4, 2014 were eligible for enrollment in the study. The exclusion criterion was 
patients aged 18 years or younger without an oncology diagnosis.  
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The study design was case-control with two separate control arms. Cases were defined as 
inpatient oncology patients whose stools tested positive for C. difficile through the Yale-New Haven 
Hospital Microbiology Laboratory. The Yale-New Haven Hospital Microbiology Laboratory 
performs a rapid glutamate dehydrogenase (GDH) antigen enzyme immunoassay (EIA) test on all 
stool samples, and if positive, performs a reflex cell culture cytotoxin test. If both tests are negative, 
then the patient is determined to be negative for C. difficile. If both tests are positive, then the 
patient is determined to be positive for C. difficile infection. However, if the GDH antigen EIA test 
is positive but the toxin EIA test is negative, a cytotoxin neutralization test in cell culture is 
performed on the sample. If this is positive, then the patient is determined to have C. difficile 
disease, while if it is negative, then the patient is determined to be colonized with C. difficile and is 
not indicative of disease or active infection. 
There were two control groups in this study. The first control group consisted of patients 
presenting with loose stools during the admission period and whose stools were submitted to the 
Microbiology Laboratory but tested negative for C. difficile. This control group was selected in 
order to determine risk factors for C. difficile infection compared to oncology patients who 
presented with loose stools but did not have C. difficile. The negative C. difficile test control 
subjects were selected at random using the random number generator function on Microsoft Excel 
from a computer-generated list of all patients who had been tested for C. difficile during the study 
period and whose stools had been submitted from the oncology wards.  
A second control group consisted of oncology patients matched to cases based on hospital 
ward and dates of admission in order to control for environmental exposure to C. difficile [21]. This 
control group was matched to cases on a 1:2 case-control ratio. From a computer-generated list of 
all patients discharged from the oncology wards during the study period, patients were matched to 
cases manually, first by hospital ward, and then by discharge date. Control patients were matched to 
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cases using a discharge date range of ±3 days. If a case had more than two control patients matched 
by hospital ward and discharge date, two control patients were selected at random using the random 
number generator function on Microsoft Excel. 
 
Data Collection 
All subjects, cases and controls, were assigned a subject identification number, which was 
used for data entry in order to eliminate patient identifiable information on data forms. All patient 
medical records were accessed through the electronic medical record system. Data was stored both 
on paper and electronically. Paper forms were kept in a locked storage cabinet. Electronic data was 
entered on a Microsoft Excel spreadsheet and stored on a HIPAA-secured network accessed through 
an encrypted computer.  
Multiple demographic and clinical variables were abstracted from patient medical records. 
The relevant risk period for C. difficile infection was established as 90 days prior to C. difficile test 
for the cases and the negative test control group, and 90 days prior to admission date for the 
matched control group. Demographic data such as age of subject and sex were collected. Dates of 
index admission and discharge and cumulative days of hospitalization in the 90 days prior to the C. 
difficile test (for the cases and negative test control group) or the index admission (for the matched 
control group) were recorded. Previous medical history such as prior history of C. difficile, type of 
cancer, stage of cancer, and cancer treatment (chemotherapy, surgery, stem cell therapy, blood 
transfusion, radiation therapy) received in the 90 days prior to the test or the index discharge were 
also recorded. Clinical variables included vancomycin-resistant enterococcus (VRE) colonization 
status, co-infections, indwelling medical devices on current admission, clinical presentation, and 
clinical outcome and treatment. For clinical presentation, the variables of elevated creatinine, fever, 
hypotension, and tachycardia were assessed at the time of the C. difficile test, while elevated lactic 
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acid, loose bowel movements, and neutropenia were assessed in the 90 days prior to the test. 
Elevated creatinine was defined as equal to or greater than 1.5 times the creatinine level on index 
admission, elevated lactic acid was defined as greater than 1.2 mmol/L, fever was defined as equal 
to or greater than a temperature of 100.4°F, hypotension was defined as systolic blood pressure 
equal to or less than 90 mmHg, and tachycardia was defined as heart rate equal to or greater than 
110 beats per minute. Antibiotics received in the risk period were noted, as well as whether they 
were received at the time of the test, prior to index admission, or discontinued after diagnosis.  
Univariate analysis was conducted for all variables to determine the descriptive statistics 
such as mean, frequencies, and standard deviations for each patient group. For the categorical 
variables, logistic regression and the Fisher’s exact test was used to determine whether variables 
were significantly associated with C. difficile infection. For continuous variables, the Student’s t test 
was used to determine association. Conditional logistic regression was used to find associations 
between the cases and the matched control group. For the multivariate model, all variables were 
input into the model and a backward stepwise elimination strategy was used to obtain the final 
model. All tests were two-tailed with a significance level of α=0.05. Data were processed and 
analyzed using Microsoft Excel (version 14.32, Microsoft Corporation) and SAS (version 9.3, SAS 
Institute, Inc.) software.  
 
Study Approval  
The study design and all protocols were reviewed and approved by the Institutional Review 







Eighty-one cases had a positive C. difficile test from the oncology wards during the period 
February 1, 2013 to June 4, 2014. Four cases were excluded because the patients did not have 
cancer, and a total of 77 cases met the eligibility criteria and were included in the study as cases. Six 
hundred seventy patients had a negative C. difficile test while on one of the oncology wards during 
the study period. Of this group of patients, 77 controls were selected for the negative test control 
group through randomization. A total of 6,933 patients were discharged during the study period 
from the oncology wards. Of this patient population, patients were matched to cases based on ward 
and discharge date as described in the methods. Two control subjects were matched to each case 
with the exclusion of two cases. For these two cases, only one control for each case was found to 
meet the matching criteria. The study included 306 subjects in total, with 77 cases, 77 patients in the 
negative test control group, and 152 patients in the matched control group. 
 Table 1 summarizes the demographic and clinical characteristics of subjects in all three 
groups. Clinical presentation on the C. difficile test date was recorded for cases and the negative test 
control group but not the matched control group since the matched control group was not tested for 
C. difficile. Significant differences between cases and the negative test control group were found in 
the proportion of subjects with prior history of C. difficile (p=0.0026), mean days of hospitalization 
in the 90 days prior to the test (p=0.0028), history of stem cell therapy (p=0.0046), and fever on the 
test date (p=0.0032). Significant differences between cases and the matched control group were 
found in mean age (p=0.0011), proportion of subjects with prior history of C. difficile (p<0.0001), 
history of blood transfusion (p=0.0134), any co-infection (p<0.0001), bloodstream infection 
(p=0.0438), wound/skin infection (p=0.0033), urinary tract infection (p=0.0171), and pneumonia 
(p=0.0059). The difference in proportion of subjects in each group who received chemotherapy in 
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the 90 days prior to the test date or index discharge was not significant between cases and the two 
groups. However, the most common chemotherapeutic agents received in each group varied. For 
cases, the most common chemotherapeutic drugs received were cytarabine (7.14%), doxorubicin 
(5.56%), cyclophosphamide (5.56%), irinotecan (5.56%), and paclitaxel (5.56%). In the negative 
test control group, the most common chemotherapeutic drugs received were cytarabine (7.69%), 
idarubicin (6.92%), cyclophosphamide (6.15%), and melphalan (6.15%), while in the matched 
control group, they were cytarabine (7.28%), cisplatin (7.28%), cyclophosphamide (6.80%), 
etoposide (6.63%), and methotrexate (5.53%).  
Table 2 displays various antibiotics received in all three groups. A significantly greater 
number of cases received clindamycin (p=0.0314) and metronidazole (p=0.0329) in the 90 days 
prior to their C. difficile test compared to the negative test control group. There was also a 
significantly higher proportion of individuals who received beta-lactams/beta-lactamase inhibitor 
(BLI) (p=0.0018), clindamycin (p=0.0065), and fluoroquinolones (p=0.0069) prior to admission in 
the cases compared to the negative test control group. Beta-lactams/BLI (p=0.0205) and 
cephalosporins (p=0.0230) were discontinued after diagnosis in significantly higher numbers in the 
cases compared to the negative test control group. There were no significant differences in 
antibiotics received at the time of the test between the cases and the negative test control group. For 
antibiotics received in the 90 days prior to the test or index discharge in cases compared to the 
matched control group, proportions of patients who received beta-lactams (p=0.0182), beta-
lactams/BLI (p=0.0002), cephalosporins (p=0.0364), metronidazole (p<0.0001), and intravenous 
vancomycin (0.0002) were significantly higher in cases. Additionally, a significantly higher number 
of cases received beta-lactams (p=0.0187), beta-lactams/BLI (p<0.0001), cephalosporins 
(p=0.0028), clindamycin (p=0.0079), fluoroquinolones (p<0.0001), metronidazole (p<0.0001), 
 15 
sulfonamides (p=0.0438), and intravenous vancomycin (<0.0001) prior to admission compared to 
the matched control group.  
 
Table 1: Demographic Factors, Medical History, and Clinical Factors by Group 
Characteristics Case (n=77) Negative Test Control (n=77) 
Matched Control 
(n=152) 
 % No. % No. % No. 
Mean age (years) 63.37 ± 13.24  61.41 ± 13.85 
 
56.68 ± 14.80  
Male 40.26 31 40.26 31 38.16 58 
Mean days of hospitalization  15.97 ± 18.81  8.88 ± 8.13  
13.37 ± 14.11  
Prior history of C. difficile 18.18 14 2.6 2 0.66 1 
VRE colonization  20.69 12 12.96 7 14.29 13 
Cancer type      
  
      Solid tumors 72.73 56 61.04 47 72.37 110 
      Hematologic cancers 32.47 25 44.16 34 27.63 42 
Cancer treatment      
  
      Blood transfusion 38.96 30 37.66 29 23.03 35 
      Chemotherapy 67.53 52 72.73 56 60.53 92 
      History of stem cell  
      therapy 3.90 3 19.48 15 7.24 11 
      Radiation therapy 7.79 6 9.09 7 10.53 16 
      Surgery 36.36 28 23.38 18 36.18 55 
Indwelling medical devices       
  
      Central venous catheter 63.64 49 68.83 53 52.63 80 
      Enteral feeding 3.90 3 6.49 5 5.92 9 
      Mechanical ventilation 3.90 3 6.49 5 4.61 7 
      Nasogastric tube 15.58 12 12.99 10 7.24 11 
      TPN 6.49 5 3.9 3 3.95 6 
Co-infections     
  
      Any co-infection 51.95 40 48.05 37 19.74 30 
      Blood stream-infection 11.69 9 5.19 4 3.95 6 
      Pneumonia 12.99 10 9.09 7 2.63 4 
      Urinary tract infection 14.29 11 15.58 12 1.97 3 
      Would/skin infection 11.69 9 10.39 8 4.61 7 
Clinical presentation      
  
      Elevated creatinine  1.30 1 2.6 2 
      Elevated lactic acid  12.99 10 3.9 3 
      Fever  24.68 19 6.49 5 
      Hypotension  11.69 9 2.60 2 
      Loose bowel movements  41.56 32 29.87 23 
      Neutropenia  33.77 26 31.17 24 




Table 2: Antibiotics Received by Group  
Antibiotic  Case (n=77) Negative Test Control (n=77) 
Matched Control 
(n=152) 
 % No. % No. % No. 
Antibiotic received in 90 days prior to test      
  
Beta-lactams 11.69 9 9.09 7 3.29 5 
Beta-lactams/BLI 58.44 45 45.45 35 32.24 49 
Carbapenems 5.19 4 1.30 1 1.32 2 
Cephalosporins 59.74 46 49.35 38 44.74 68 
Clindamycin 12.99 10 2.60 2 5.92 9 
Colistin 0.00 0 0.00 0 0.66 1 
Daptomycin 1.30 1 0.00 0 1.32 2 
Fluoroquinolones 53.25 41 50.65 39 44.08 67 
Fosfomycin 2.60 2 0.00 0 0.00 0 
Metronidazole 37.66 29 20.78 16 9.21 14 
Sulfonamides 14.29 11 12.99 10 9.87 15 
Tigecycline 0.00 0 0.00 0 0.66 1 
Vancomycin (intravenous) 49.35 38 41.56 32 24.34 37 
Vancomycin (oral) 2.60 2 0.00 0 0.00 0 
Antibiotic received prior to admission a      
  
Beta-lactams 7.79 6 2.60 2 1.32 2 
Beta-lactams/BLI 33.77 26 11.69 9 7.89 12 
Carbapenems 1.30 1 0.00 0 0.00 0 
Cephalosporins 28.57 22 16.88 13 11.84 17 
Clindamycin 10.39 8 0.00 0 1.97 3 
Daptomycin 1.30 1 0.00 0 1.32 2 
Fluoroquinolones 46.75 36 24.68 19 14.47 22 
Fosfomycin 2.60 2 0.00 0 0.00 0 
Metronidazole 10.39 8 12.99 10 1.97 3 
Sulfonamides 11.69 9 9.09 7 3.95 6 
Vancomycin (intravenous) 24.68 19 11.69 9 5.26 8 
Vancomycin (oral) 1.30 1 0.00 0 0.00 0 
Antibiotic received at time of test a     
  
Beta-lactams 5.19 4 3.90 3   
Beta-lactams/BLI 24.68 19 28.57 22   
Carbapenems 1.30 1 0.00 0   
Cephalosporins 6.49 5 11.69 9   
Fluoroquinolones 7.79 6 19.48 15   
Metronidazole 10.39 8 12.99 10   
Sulfonamides 5.19 4 5.19 4   
Vancomycin (intravenous) 23.38 18 15.58 12   
Antibiotic discontinued after diagnosis a      
  
Beta-lactams 25.00 1 33.33 1   
Beta-lactams/BLI 38.10 8 4.76 1   
Cephalosporins 80.00 4 11.11 1   
Clindamycin 14.29 1 0.00 0   
Metronidazole 0.00 0 40.00 4   
Vancomycin (intravenous) 35.29 6 0.00 0   
 
a Antibiotics with zero frequencies across all groups were omitted 
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Table 3 displays the odds ratios from a univariate, unadjusted logistic regression of 
demographic, medical history, and clinical risk factors in cases compared to the negative test 
control group and the matched control group. For cases compared to the control group with negative 
C. difficile test results, days of hospitalization in the 90 days prior to the test date, prior history of C. 
difficile, fever on the test date, and hypotension on the test date were all significantly associated 
with C. difficile infection in cases compared to the negative test control group. Increasing days of 
hospitalization in the past 90 days prior to the C. difficile test was associated with 1.054 (95% CI 
1.017, 1.092) times the odds of having a positive C. difficile infection. Prior history of C. difficile 
was associated with 8.333 (95% CI 1.824, 38.063) times the odds of C. difficile infection. For 
clinical presentation on the test date, the odds of C. difficile infection were 4.717 (95% CI 1.661, 
13.400) for fever and 4.963 (95% CI 1.036, 23.781) for hypotension. In contrast, history of stem 
cell therapy was negatively associated with C. difficile infection. Patients with a history of stem cell 
therapy were significantly less likely (OR=0.168, 95% CI 0.046, 0.606) to have positive C. difficile 
infection.  
For the univariate analysis of cases compared to the matched control group, age, prior 
history of C. difficile, blood transfusion, having any co-infection, as well as the co-infections of 
blood-stream infection, pneumonia, urinary tract infection, and would/skin infection were 
significantly associated with risk of C. difficile infection. Increasing age was associated with 1.036 
(95% CI 1.013, 1.060) times the odds of having positive C. difficile infection. Patients with a prior 
history of C. difficile had 27-fold higher odds of having C. difficile infection (OR=27.035, 95% CI 
3.551, 205.826). Patients who received blood transfusion for cancer treatment in the 90 days prior to 
index admission were 2.168 (95% CI 1.161, 4.048) times as likely to have C. difficile infection. 
Having any co-infection was associated with a 3.830 (95% CI 2.113, 6.944) times the odds of 
having C. difficile infection. For specific co-infections, the odds were 3.221 (95% CI 1.102, 9.411) 
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for blood stream infections, 5.522 (95% CI 1.672, 18.242) for pneumonia, 3.452 (95% CI 1.281, 
9.303) for urinary tract infections, and 6.574 (95% CI 1.725, 25.048) for wound/skin infections. 
 
Table 3: Univariate Logistic Regression of Potential Risk Factors in Cases Compared to 
Control Groups 
 Negative Test Control (n=77) Matched Control (n=152) 
 OR (95% CI) OR (95% CI) 
Age  1.010 (0.987, 1.034) 1.036 (1.013, 1.060) 
Gender         Male 1.000 1.000 
      Female 1.000 (0.525, 1.904) 0.895 (0.488, 1.641) 
Days of hospitalization 1.054 (1.017, 1.092) 1.011 (0.993, 1.030) 
Prior history of C. difficile  8.333 (1.824, 38.063) 27.035  (3.551, 205.826) 
VRE colonization  1.752 (0.634, 4.842) 1.532 (0.624, 3.760) 
Cancer type          Hematologic 0.608 (0.316, 1.171) 1.490 (0.625, 3.548) 
      Solid tumors 1.702 (0.863, 3.357) 1.123 (0.494, 2.553) 
Cancer treatment          Blood transfusion 1.056 (0.552, 2.023) 2.168 (1.161, 4.048) 
      Chemotherapy 0.780 (0.390, 1.558) 1.515 (0.760, 3.017) 
      History of stem cell therapy 0.168 (0.046, 0.606) 0.442 (0.115, 1.705) 
      Radiation therapy 0.845 (0.271, 2.641) 0.702 (0.247, 1.997) 
      Surgery 1.873 (0.927, 3.783) 1.048 (0.503, 2.183) 
Indwelling medical devices          Central venous catheter 0.792 (0.406, 1.548) 1.700 (0.913, 3.165) 
      Enteral feeding 0.584 (0.135, 2.533) 0.537 (0.104, 2.786) 
      Mechanical ventilation 0.584 (0.135, 2.533) 0.843 (0.204, 3.491) 
      Nasogastric tube 1.237 (0.500, 3.060) 2.315 (0.962, 5.572) 
      TPN 1.713 (0.395, 7.433) 1.667 (0.509, 5.461)  
Co-infections         Any co-infection 1.169 (0.621, 2.199) 3.830 (2.113, 6.944) 
      Blood stream infection 2.415 (0.711, 8.205) 3.221 (1.102, 9.411) 
      Pneumonia 1.493 (0.537, 4.149) 5.522 (1.672, 18.242) 
      Urinary tract infection 0.903 (0.372, 2.192) 3.452 (1.281, 9.303) 
      Would/skin infection 1.141 (0.416, 3.132) 6.574 (1.725, 25.048) 
Clinical presentation         Elevated creatinine 0.493 (0.044, 5.558) 
      Elevated lactic acid 3.682 (0.972, 13.946) 
      Fever 4.717 (1.661, 13.400) 
      Hypotension 4.963 (1.036, 23.781) 
      Loose bowel movements 1.670 (0.858, 3.250) 
      Neutropenia 1.126 (0.573, 2.211) 
      Tachycardia 1.412 (0.680, 2.933) 
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A univariate, unadjusted logistic regression was also analyzed for use of various antibiotics 
as risk factors in cases compared to both control groups (Table 4). In cases compared to the 
negative test control group, receipt of clindamycin and metronidazole in the 90 days prior to test 
were significantly associated with risk of C. difficile infection, while receipt of beta-lactams/BLI, 
clindamycin, fluoroquinolones, metronidazole, and intravenous vancomycin prior to index 
admission were significantly associated with increased risk of C. difficile infection. Clindamycin 
was associated with 5.596 (95% CI 1.184, 26.457) times the odds of C. difficile infection if received 
at any time in the 90 days prior to test and 18.939 (95% CI 1.074, 333.333) times the odds of C. 
difficile infection if received prior to index admission. Metronidazole was associated with 2.303 (95% 
CI 1.123, 4.723) times the odds of C. difficile infection if received in 90 days prior to test and 5.978 
(95% CI 1.927, 18.541) times the odds of C. difficile infection if received prior to index admission. 
The odds of C. difficile infection for antibiotics received prior to admission were 3.852 (95% CI 
1.662, 8.926) for beta-lactams/BLI, 2.680 (95% CI 1.351, 5.315) for fluoroquinolones, and 2.475 
(95% CI 1.040, 5.889) for intravenous vancomycin. 
A greater number of antibiotics were significantly associated with higher risk of C. difficile 
infection in cases compared to the matched control group. The odds of C. difficile infection for 
antibiotics received in the 90 days prior to index discharge were 4.165 (95% CI 1.271, 13.653) for 
beta-lactams, 3.160 (95% CI 1.704, 5.858) for beta-lactams/BLI, 1.870 (95% CI 1.048, 3.336) for 
cephalosporins, 6.754 (95% CI 2.924, 15.599) for metronidazole, and 3.048 (95% CI 1.659, 5.600) 
for vancomycin. The odds of C. difficile infection for antibiotics received prior to admission were 
6.000 (95% CI 1.211, 29.727) for beta-lactams, 8.242 (95% CI 3.126, 21.727) for beta-lactams/BLI, 
2.728 (95% CI 1.376, 5.409) for cephalosporins, 5.333 (95% CI 1.415, 20.103) for clindamycin, 
5.457 (95% CI 2.669, 11.158) for fluoroquinolones, 33.103 (95% CI 4.412, 248.357) for 
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metronidazole, 3.000 (95% CI 1.068, 8.428) sulfonamides, and 8.087 (95% CI 2.722, 24.029) for 
intravenous vancomycin.  
 
Table 4: Univariate Logistic Regression of Antibiotic Use in Cases Compared to Control 
Groups 
  
 Negative Test Control (n=77) 
Matched Control  
(n=152) 
 OR (95% CI) OR (95% CI) 
Antibiotic received in 90 days prior to test    Beta-lactams 1.324 (0.467, 3.754) 4.165 (1.271, 13.653) 
Beta-lactams/BLI 1.687 (0.892, 3.193) 3.160 (1.704, 5.858) 
Carbapenems 4.164 (0.455, 38.139) 4.000 (0.733, 21.838) 
Cephalosporins 1.523 (0.804, 2.882) 1.870 (1.048, 3.336) 
Clindamycin 5.596 (1.184, 26.457) 2.788 (0.983, 7.908) 
Daptomycin 3.039 (0.122, 75.757) 1.000 (0.091, 11.028) 
Fluoroquinolones 1.110 (0.590, 2.089) 1.430 (0.811, 2.521) 
Metronidazole 2.303 (1.123, 4.723) 6.754 (2.924, 15.599) 
Sulfonamides 1.117 (0.444, 2.806) 1.550 (0.671, 3.582) 
Vancomycin (intravenous) 1.370 (0.725, 2.589) 3.048 (1.659, 5.600) 
Antibiotic received prior to admission    Beta-lactams 3.169 (0.619, 16.221) 6.000 (1.211, 29.727) 
Beta-lactams/BLI 3.852 (1.662, 8.926) 8.242 (3.126, 21.727) 
Cephalosporins 1.969 (0.908, 4.273) 2.728 (1.376, 5.409) 
Clindamycin 18.939 (1.0743, 333.333) 5.333 (1.415, 20.103) 
Daptomycin 3.039 (0.122, 75.757) 1.000 (0.091, 11.028) 
Fluoroquinolones 2.680 (1.351, 5.315) 5.457 (2.669, 11.158) 
Metronidazole 5.978 (1.927, 18.541) 33.103 (4.412, 248.357) 
Sulfonamides 1.324 (0.467, 3.754) 3.000 (1.068, 8.428) 
Vancomycin (intravenous) 2.475 (1.040, 5.889) 8.087 (2.722, 24.029) 
Antibiotic received at time of test    Beta-lactams 1.352 (0.292, 6.251)  
Beta-lactams/BLI 0.819 (0.400, 1.676)  
Carbapenems 3.039 (0.122, 75.757)  
Cephalosporins 0.525 (0.167, 1.645)  
Fluoroquinolones 0.349 (0.128, 0.955)  
Metronidazole 0.777 (0.289, 2.088)  
Sulfonamides 1.000 (0.241, 4.151)  
Vancomycin (intravenous) 1.830 (0.800, 4.190)  
 
 
 In a multivariate logistic regression model comparing cases to the negative test control 
group (Table 5), days of hospitalization in the 90 days prior to the test, fever on the test date, prior 
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history of C. difficile, and hypotension were all significantly associated with higher likelihoood of C. 
difficile infection, adjusting for all other variables. Increasing days of hospitalization was associated 
with slightly increased odds of C. difficile infection, at an odds ratio of 1.075 (95% CI 1.027, 1.124). 
Fever on the test date was associated with a five-fold increase in likelihood of C. difficile 
(OR=5.232, 95% CI 1.460, 18.755) and hypotension on the test date was associated with a nine-fold 
increase in likelihood of C. difficile infection (OR=9.245, 95% CI 1.235, 69.183). Prior history of C. 
difficile carried the highest likelihood of C. difficile infection of the variables in the model, at a 32-
fold increase in likelihood of C. difficile infection (OR=32.433, 95% CI 3.513, 299.445). In the 
same model, history of stem cell therapy and radiation therapy as cancer treatment in the 90 days 
prior to the test were significant for reduced likelihood of C. difficile infection. History of stem cell 
therapy was associated with 0.043 times (95% CI 0.006, 0.313) the odds of C. difficile infection, 
and patients who received radiation therapy for cancer treatment in the 90 days prior to the C. 
difficile test were nine-fold less likely to have C. difficile infection (OR=0.096, 95% CI 0.016, 
0.594). All significant variables in the multivariate, adjusted model were also significant in the 
univariate model with the exclusion of radiation therapy. Antibiotics that were significantly 
associated with increased likelihood of C. difficile in the univariate analysis, however, were not 
significant in the multivariate, adjusted model.  
 
Table 5: Multivariate Logistic Regression Compared to Negative Test Control Group 
	  
Characteristic OR (95% CI) 
   Days of hospitalization 1.075 (1.027, 1.124) 
Fever 5.232 (1.460, 18.755) 
History of C. difficile 32.433 (3.513, 299.445) 
History of stem cell therapy 0.043 (0.006, 0.313) 
Hypotension 9.245 (1.235, 69.183) 
Radiation therapy 0.096 (0.016, 0.594) 
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For cases compared to the matched control group, the multivariate logistic regression model 
showed that age, any co-infection, blood transfusion, cephalosporins, chemotherapy, prior history of 
C. difficile infection, metronidazole, and the presence of a nasogastric tube were significantly 
associated with higher risk of C. difficile infection. Fluoroquinolones, mechanical ventilation, 
radiation therapy, and TPN were associated with lower risk of C. difficile infection, adjusting for all 
other variables. Increasing age was associated with slightly increased odds of C. difficile infection 
of 1.042 (95% CI 1.006, 1.079). Patients with any co-infection were 5.614 (95% CI 1.878, 16.787) 
times more likely to have C. difficile infection. Certain cancer treatments were associated with 
increased risk of C. difficile. Blood transfusion was associated with 3.200 (95% CI 1.251, 8.183) 
times the odds of C. difficile infection, while chemotherapy was associated with 5.069 (95% CI 
1.609, 15.972) times the odds of C. difficile infection. Patients who received cephalosporins in the 
90 days prior to the index discharge were 4.214 (95% CI 1.371, 12.952) times more likely to have C. 
difficile infection, and patients who received metronidazole were 16.005 (95% CI 3.958, 64.713) 
times more likely to have C. difficile infection. Prior history of C. difficile was associated with an 
almost 28-fold increase (OR=27.806, 95% CI 2.484, 311.290) in likelihood of C. difficile infection 
during the index admission. The presence of a nasogastric tube during the index admission was 
associated with a seven-fold increase (OR=6.988, 95% CI 1.339, 36.477) in likelihood of C. difficile 
infection. In contrast, receiving fluoroquinolones was associated with a reduced likelihood of C. 
difficile infection (OR=0.286, 95% CI 0.097, 0.846), and mechanical ventilation was also associated 
with a reduced likelihood (OR=0.056, 95% CI 0.004, 0.817) of C. difficile infection. Patients who 
received radiation therapy were 0.117 (95% CI 0.016, 0.872) times as likely to have C. difficile 
infection, and patients who received TPN were 0.108 (95% CI 0.015, 0.834) times as likely. The co-
infections of blood stream infection, pneumonia, urinary tract infection, and wound/skin infections 
were each individually significantly associated with C. difficile infection in the univariate analysis 
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but were not significant in the multivariate, adjusted model. In contrast, chemotherapy, mechanical 
ventilation, nasogastric tube, radiation therapy, and TPN were not significant in the univariate 
model but were significant in the multivariate, adjusted model. Of the antibiotics that were found to 
be significant in the univariate model, only receipt of cephalosporins, fluoroquinolones, and 
metronidazole in the 90 days prior to the index discharge were significant in the multivariate, 
adjusted model.  
 
Table 6: Multivariate Logistic Regression Compared to Matched Control Group  
	  
Characteristic OR (95% CI) 
   Age 1.042 (1.006, 1.079) 
Any co-infection 5.614 (1.878, 16.787) 
Blood transfusion 3.200 (1.251, 8.183) 
Cephalosporins 4.214 (1.371, 12.952) 
Chemotherapy 5.069 (1.609, 15.972) 
Fluoroquinolones 0.286 (0.097, 0.846) 
History of C. difficile 27.806 (2.484, 311.290) 
Mechanical ventilation 0.056 (0.004, 0.817) 
Metronidazole 16.005 (3.958, 64.713) 
Nasogastric tube 6.988 (1.339, 36.477) 
Radiation therapy 0.117 (0.016, 0.872) 






	   The study found several significant associations between C. difficile infection and various 
demographic characteristics, clinical factors, antibiotics, and medical history. By using two control 
groups, this study was able to find distinct associations for C. difficile-associated diarrhea in 
oncology patients presenting with diarrhea (the negative test control group) and for C. difficile 
infection in a more general group of oncology patients (the matched control group).  
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Cases Compared to the Negative Test Control Group 
 Between the cases and the negative test control group, univariate, unadjusted analyses found 
that the days of hospitalization in the 90 days prior to test, prior history of C. difficile, fever on test 
date, hypotension on test date, receipt of clindamycin in 90 days prior to C. difficile test, receipt of 
metronidazole in 90 days prior to C. difficile test, receipt of beta-lactams/BLI prior to admission, 
receipt of clindamycin prior to admission, receipt of fluoroquinolones prior to admission, receipt of 
metronidazole prior to admission, and receipt of intravenous vancomycin prior to admission were 
significantly associated with increased likelihood of C. difficile infection. Surprisingly, history of 
stem cell therapy was significantly associated with reduction in likelihood C. difficile infection. 
However, the associations between the cases and the negative test control group may reflect the 
likelihood of positive C. difficile test rather than the odds of disease, as testing bias may impact the 
associations.  
Days of hospitalization in the 90 days prior to test may be associated with C. difficile 
infection for multiple reasons. First, days of hospitalization may reflect severity of underlying 
cancers, and subsequently, increased host susceptibility to infection. Recent hospitalization may 
also indirectly represent recent exposure to other risk factors, such as antibiotic use and 
immunosuppressive therapies, both of which have been implicated as risk factors for C. difficile 
infection in previous studies [12, 14]. Days of hospitalization may also correlate to increased 
exposure to C. difficile in the healthcare setting through increased length of exposure to any 
environmental spores or exposure to asymptomatic carriers of toxigenic strains of C. difficile. 
Although most asymptomatic carriage of C. difficile is with non-toxigenic strains, studies have 
shown that there are individuals who are asymptomatic and carry toxigenic strains of C. difficile. If 
there were patients in the study wards who were asymptomatically colonized with toxigenic strains, 
they may have contributed to nosocomial transmission of C. difficile [22, 23]. Prior history of C. 
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difficile is another factor in patients’ medical histories that has previously been identified as a risk 
factor for C. difficile infection; recurrent C. difficile is common. Relapse rates have been found to 
range from 5-23% for metronidazole-treated C. difficile and 9-24% for patients treated with oral 
vancomycin [24]. Re-infections are common as well. A study found that 56% of clinical recurrences 
of C. difficile are due to re-infections rather than relapses [25]. Thus, patients with prior history of C. 
difficile may have been susceptible to re-infection or relapse upon index admission.  
In terms of clinical presentation, cases were more likely to present with fever and 
hypotension on the day of the C. difficile test compared to patients in the negative test control group, 
and these associations were statistically significant. There were higher proportions of cases with 
elevated lactic acid in the 90 days prior to test, loose bowel movements in the 90 days prior to test, 
neutropenia in the 90 days prior to test, and tachycardia on the test date compared to the negative 
test control group, but these differences in proportions were not significant. This finding has 
implications for clinicians who are treating cancer patients with diarrhea. Poorer clinical 
presentation, particularly fever and hypotension, on days of diarrhea may increase suspicion for C. 
difficile infection.  
All antibiotics assessed in this study were received in higher proportions in cases compared 
to the negative test control group if received in the 90 days prior to the test or prior to admission, 
though only a few associations were statistically significant. Receipt of clindamycin and 
metronidazole in the 90 days prior to the test were significantly associated with C. difficile infection 
in cases compared to the negative test control group, and receipt of beta-lactams/BLI, clindamycin, 
fluoroquinolones, metronidazole, and intravenous vancomycin prior to admission (i.e., on a 
previous hospitalization within 90 days prior to the index admission) were significantly associated 
with C. difficile. The associations between clindamycin, fluoroquinolones, and beta-lactams/BLI 
with C. difficile infection are consistent with previous studies [26]. Metronidazole, however, is often 
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used as treatment for C. difficile infections, so the association between metronidazole use and C. 
difficile may be confounded by recent history of C. difficile, particularly since prior history of C. 
difficile was also significantly associated with positive C. difficile test. Intravenous vancomycin has 
also previously not been commonly associated with C. difficile infection. However, intravenous 
vancomycin is a commonly prescribed antibiotic particularly for empirical use, so the frequency of 
intravenous vancomycin received in cases may be more reflective of general antibiotic prescription 
practices based on the patients’ poorer clinical presentation or their increased days of hospitalization 
prior to C. difficile infection [27].  
Of the cancer treatments, history of stem cell therapy was the only significant association, 
and the association between history of stem cell therapy and C. difficile infection was negative. This 
was an unexpected finding, as stem cell therapy is typically performed in conjunction with 
immunosuppressive agents, and immunosuppression is an established risk factor for C. difficile 
infection [14, 28]. However, the association found in this study may reflect the higher percentage of 
patients in the negative test control group with hematologic cancers compared to the cases. 
Additionally, diarrhea is a frequent complication of stem cell transplantation for patients with 
lymphoma and multiple myeloma, so there may have been selection bias in the negative test control 
group. Patients with lymphoma and multiple myeloma who had a history of stem cell therapy may 
have been selected more frequently into the negative test control group because they exhibited 
greater frequency of diarrhea than patients with other cancers, which resulted in their stool samples 
being tested more frequently [29]. 
Adjusting for all other variables, the multivariate model comparing cases to the negative 
case control group found days of hospitalization, fever on the test date, hypotension on the test date, 
and prior history of C. difficile to be significantly associated with C. difficile infection. History of 
stem cell therapy was once again associated with reduced likelihood of C. difficile infection, as well 
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as radiation therapy in 90 days prior to C. difficile test, which was not significant in the univariate 
analysis. Radiation therapy, like stem cell therapy, is typically associated with immunosuppression 
and has been associated with decreased intestinal microflora, which is a risk factor for acquisition of 
toxigenic C. difficile strains [30]. Thus, this finding was unexpected and a similar association has 
not been found in previous studies. Further studies should be conducted to assess for possible 
confounders in the negative association between radiation therapy and C. difficile infection. None of 
the antibiotics were independently associated with increased risk of C. difficile infection in the 
adjusted model that controlled for all other variables; however, this finding does not necessarily 
indicate that antibiotic use is not a risk factor for C. difficile infection.  
 
Cases Compared to the Matched Control Group 
Between the cases and the control group matched to cases based on hospital ward and date 
of discharge, increasing age, prior history of C. difficile, blood transfusion, any co-infection, blood 
stream infection, pneumonia, urinary tract infection, and wound/skin infection were significantly 
associated with C. difficile infection in the univariate, unadjusted analysis. For the univariate, 
unadjusted analysis examining antibiotic use between cases and the matched control group, receipt 
of beta-lactams, beta-lactams/ BLI, cephalosporins, metronidazole, and intravenous vancomycin in 
the 90 days prior to test were significantly associated with C. difficile infection, and receipt of beta-
lactams, beta-lactams/BLI, cephalosporins, clindamycin, fluoroquinolones, metronidazole, 
sulfonamides, and intravenous vancomycin prior to admission were significantly associated with C. 
difficile.  
The study’s finding of a positive association between increasing age and C. difficile 
infection is consistent with previous studies that identified increasing age to be a risk factor for C. 
difficile [12]. All co-infections that were assessed in the study were significantly associated with C. 
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difficile infection in the univariate analyses, and this is also consistent with previous associations 
found between C. difficile and severity of underlying disease [12]. Of cancer treatments, only blood 
transfusion was significantly associated with C. difficile infection. Blood transfusion has been 
known to cause immunomodulation in the recipient, and in particular, immunosuppression [31]. It is 
possible that blood transfusion increased the likelihood of C. difficile infection through 
immunosuppression, thereby increasing host susceptibility. Additionally, a study found that in 
children with cancer, C. difficile infection was significantly associated with blood transfusions, 
possibly due to immunosuppression following blood transfusions [32]. Although our study did not 
enroll children under the age of 18, it is possible that in both pediatric and adult oncology patients, 
there is a similar mechanism that increases susceptibility to C. difficile infection after receiving 
recent blood transfusion; however, the exact mechanism is yet unknown and warrants further 
research.  
Beta-lactams, beta-lactams/BLI, cephalosporins, clindamycin, and fluoroquinolones have all 
been previously associated with C. difficile infection [33]. Although a study has found a significant 
association between sulfonamides and C. difficile infection, sulfonamides are a class of antibiotics 
that have typically been less frequently associated with C. difficile infection [34]. Intravenous 
vancomycin has also previously been rarely associated with C. difficile infection, but in this study, 
recent receipt of intravenous vancomycin was significantly associated with C. difficile infection in 
univariate analyses in cases compared to both control groups. The identification of antibiotics that 
have previously been less commonly associated with C. difficile in this study could reflect changes 
in prescription practices or the identification of novel antimicrobial risk factors in C. difficile.  
There were several unexpected effects found in the multivariate regression model comparing 
the cases to the matched control group. First, receipt of fluoroquinolones in the 90 days prior to the 
test appeared to have a negative association with C. difficile infection. However, fluoroquinolones 
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have been previously identified as a risk factor for C. difficile infection in several studies [35, 36]. 
Consistent with previous studies, the univariate analysis showed an insignificant but positive 
association between fluoroquinolones and C. difficile infection for fluoroquinolones received in the 
90 days prior to the test, and a significant, positive association between fluoroquinolones received 
prior to admission and C. difficile. In our study, antibiotics received in the 90 days prior to the test 
was a distinct variable from antibiotics received prior to admission, since the antibiotics received 
prior to admission excluded the antibiotics received prior to test but during the index admission. In 
the multivariate model, antibiotics used in the 90 days prior to test was included but not the 
antibiotics received prior to admission as these variables were overlapping for many of the subjects; 
however, the reversal of association found in the multivariate model is still surprising given prior 
studies. It is possible that the negative association in the multivariate model is due to 
multicollinearity, in which the variable of fluoroquinolones is strongly correlated with another 
variable in the multiple regression model, or there could be a confounder in the model. However, it 
is not readily apparent whether any of the variables in the model lies in the causal pathway between 
fluoroquinolones and C. difficile and would be a confounder of this association. Another possible 
explanation is the reversal paradox, also known as the Simpson’s paradox, Lord’s paradox, or the 
suppression effect. This paradox refers to the phenomenon in which the association between two 
variables is reversed, diminished, or enhanced when additional variables are controlled for [37]. 
This paradox is commonly observed in conditional analyses in particular, which is consistent with 
the use of the conditional multivariate logistic regression for the model comparing cases to the 
matched control group [38]. It is possible that the reversal in association for fluoroquinolones and C. 
difficile is due to this paradox; however, there is a lack of consensus in the literature regarding the 
correct interpretation of results when the reversal paradox occurs, so it is unclear whether the 
univariate results or the multivariate results should be considered the true association. However, 
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because there have been numerous studies showing a positive association between fluoroquinolones 
and C. difficile infection, it is likely that the positive association found in this study’s univariate 
analyses may be more reflective of the true association. The negative association between total 
parenteral nutrition and C. difficile also appears to be affected by the reversal paradox in the 
multivariate model, as the univariate analysis shows a non-significant but positive association 
between TPN and C. difficile. The interpretation of this is less clear, as there have been limited 
previous studies examining the association between TPN and C. difficile. This is an association that 
warrants further investigation.  
Other factors that were not affected by the reversal paradox but negatively associated with C. 
difficile infection in the multivariate model comparing cases to the matched control group were 
mechanical ventilation on index admission and radiation therapy in the 90 days prior to index 
discharge. Radiation therapy was also found to be significantly associated with reduced likelihood 
of C. difficile infection in the multivariate analysis comparing cases to the negative test control 
group, and poses an unexpected finding. The negative association between C. difficile and 
mechanical ventilation was also unexpected, as mechanical ventilation often indicates more severe 
underlying disease. Additionally, the association between nosocomial pneumonia and ventilators 
has been well established, and ventilators have long been implicated as a major cause of nosocomial 
bacterial colonization [39]. Radiation therapy and mechanical ventilation both require further 
research to determine the association between these factors and risk of C. difficile infection.  
The multivariate model found several significant positive associations for C. difficile 
infection. Increasing age, any co-infection, recent blood transfusion, receipt of cephalosporins in the 
90 days prior to the index discharge, recent chemotherapy, prior history of C. difficile, receipt of 
metronidazole in the 90 days prior to the index discharge, and presence of a nasogastric tube were 
associated with increasing likelihood of C. difficile infection. All of these variables were also 
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significantly associated with C. difficile infection in the univariate analyses with the exception of 
chemotherapy and nasogastric tube. Both chemotherapy and nasogastric tubes have been associated 
with C. difficile in previous studies, and this study shows a consistent association [12, 17]. This 
study did not examine associations between specific chemotherapeutic agents and C. difficile, but 
previous studies have shown particular chemotherapeutic agents to be associated with C. difficile. 
Thus, grouping all chemotherapeutic agents as a single variable in this study may have resulted in a 
diminished association, and future studies may benefit from examining the associations between 
specific chemotherapy drugs and C. difficile infection. 
 
Limitations  
 There are several limitations to this study. First, the study design was a retrospective, case-
control chart review. Patient medical records may be incomplete, and missing data can lead to 
biased results. In particular, several variables were difficult to find and often incompletely and 
inconsistently documented in patient medical records, such as indwelling medical devices and 
cancer staging information. Cancer staging data were so sparsely found in patients’ medical records 
that the variable was omitted in the analysis, but future studies may find analysis of cancer stage to 
be informative in exploring an association between C. difficile and severity of cancer. Patients who 
were transferred from outside facilities also often had inconsistently or incompletely documented 
charts. There may also be bias due to differential reporting and documentation between cases and 
controls. Case patients tended to have poorer prognosis and more complications during their 
hospitalizations than control patients, particularly compared to the matched control group. Thus, it 
may have been more likely for control patients to have incomplete documentation for various 
medical history and clinical factors while cases had more extensive documentation in their charts.  
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 The selection of control groups also posed a limitation. Subjects for the negative test control 
group were selected from a randomized list of patients whose stool samples were submitted to the 
Microbiology Lab for C. difficile testing and found to be negative for C. difficile toxin. However, it 
is possible that not all patients with diarrhea were tested for C. difficile, as there were no universal 
criteria for C. difficile testing in patients with diarrhea in the study hospital. This could have 
resulted in selection bias in which more clinically severely ill patients were enrolled as both cases 
and as negative test controls, because patients exhibiting milder diarrheal symptoms may not have 
had stool samples collected for C. difficile testing, and consequently, not enrolled in the study. 
Finally, the matching criteria for the matched control group were kept minimal to two factors – 
same hospital ward and date of discharge – in order to identify as many potential risk factors as 
possible. Although the matching criteria used in our study were selected to control for 
environmental factors, incorporating additional matching criteria may have been able to adjust for 
possible confounding variables.  
Another limitation with the negative test control group was that C. difficile carriage status 
was not documented. Patients who were positive for C. difficile antigen but were negative for C. 
difficile toxin in the clinical microbiology laboratory test results were identified to be negative for C. 
difficile infection but colonized with non-toxigenic C. difficile. Although patients with C. difficile 
colonization are not clinically indicated for treatment and are not considered to have active infection, 
studies have shown both common and distinct risk factors for C. difficile colonization compared to 
C. difficile infection. Healthcare-associated C. difficile colonization has been associated with 
previous hospitalization, chemotherapy, proton-pump inhibitors, H2 blockers, antibodies against 
toxin B, stool softeners, and antacids [40, 41]. Thus, by not distinguishing between C. difficile 
colonized patients and un-colonized patients in our control groups, this study may have overlooked 
the distinct risk factors that may influence C. difficile colonization versus infection.  
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The risk period during used in this study was 90 days; however, different studies have used 
shorter periods of 60 days or 30 days prior to infection to assess relevant exposures associated with 
C. difficile [42, 43, 44]. The use of a longer risk period may have resulted in the identification of 
some exposures that may not have been directly associated with C. difficile by the time of diagnosis 
for the cases. Finally, this study was conducted in a single institution with a relatively low sample 
size. Thus, the results of the study may not be applicable to a larger population of oncology patients, 
particularly in different settings where overall C. difficile prevalence may be different than that of 
our center.  
 
Conclusions 
In conclusion, this study identified several risk factors for C. difficile infection in oncology 
patients, both with and without diarrhea and suspicion of C. difficile. These findings may guide 
clinicians in selecting appropriate testing for oncology patients who may be at higher risk for C. 
difficile infection. Although diarrhea is a common complication in cancer patients, the comparison 
between the cases and the negative test control group shows that cancer patients exhibiting diarrhea 
with a fever and hypotension may be indicative for C. difficile infection. Additionally, patients with 
diarrhea who have lengthy recent hospitalization records and a prior history of C. difficile may be at 
increased risk of current C. difficile infection. Based on the analysis of the matched control group, 
reduction in cephalosporins and metronidazole use, particularly among patients with any co-
infections, presence of a nasogastric tube, a history of C. difficile infection, recent chemotherapy or 
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Appendix: Data Collection Form  
	  
Data Collection Form – C. difficile in Oncology Patients 
Subject type:   CASE         NEGATIVE TEST CONTROL       HOSPITAL TIME CONTROL 
Date of C. difficile test confirmation (cases) or negative test (controls): ____/____/____ 
Age of subject at test confirmation or at time of hospital admission:  _________                
Sex:  MALE  FEMALE 
Date of index admission: ____/____/____ 
Date of index discharge:  ____/____/____  
Days of YNHH hospitalization in 90 days prior to culture:  _____________________________ 
                  _____________________________ 
                  _____________________________ 
History of C. difficile:     YES  NO    If yes, date of prior diagnosis:___________  
Type of Cancer: ________________________________________________________________ 
 Stage:  I  II  III IV Not staged  
 
Cancer treatment 90 days prior to test: 
Chemotherapy 90 days prior to culture:    YES         NO 
Date of last chemotherapy treatment: _____/_____/_____ 
Type:__________________________________________________________________ 
Surgery:     YES NO   If yes, site(s): ____________________________________ 
History of stem cell therapy:     YES       NO 
Blood transfusion: YES NO 
Radiation therapy: YES  NO 
 
VRE colonization status:   YES  NO  UNKNOWN 
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Co-infections:          YES    NO     
 Blood stream infections    Urinary tract infections 
 Wound/skin infections   Pneumonia 
 Other: _______________________________ 
Indwelling medical devices on current admission: 
 Central Venous Catheter  YES NO     UNKNOWN 
 Urinary Catheter  YES  NO     UNKNOWN 
 Mechanical Ventilation YES NO     UNKNOWN 
 Nasogastric Tube  YES NO     UNKNOWN 
 TPN    YES  NO     UNKNOWN 
 Enteral feeding  YES  NO     UNKNOWN 
 
Antibiotic received 90 days prior to test or discharge:  
Antibiotic Received (YES/NO) 
At time of test 
(YES/NO) 







Beta-Lactam     
Beta-Lactam + BLI     
1st or 2nd generation 
cephalosporin 
    
3rd generation cephalosporin     
4th generation cephalosporin     
Carbapenem     
Fluoroquinolone     
Tigecycline     
Vancomycin (intravenous)     
Vancomycin (oral)     
Daptomycin     
Linezolid     
Metronidazole     
Clindamycin     
Sulfonamide     
Rifaxamin     
Fosfomycin     
Colistin     
Other 
_______________________ 
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Clinical presentation:  
 Temperature on test date: _______________ 
 Tmax 90 days prior to test: _______________ 
 Max heart rate: _______________________ 
 Min blood pressure: ___________________ 
 WBC count: _________________________ 
 Creatinine on admission: _______________ 
 Creatinine on test date: _________________ 
 Neutropenia 90 days prior to test:  YES  NO 
 Lactic acid 90 days prior to test: YES  NO 
Loose stool 90 days prior to test:  YES   NO 
 
Clinical outcome/treatment: 
 Treatment: ____________________________________ 
 Transferred to ICU:  YES  NO  UNKNOWN 
 Abdominal X-Ray:  YES  NO    
 CAT Scan:   YES  NO   
If yes, evidence of colitis?:   YES  NO 
 Colectomy:   YES  NO   
 Death:   YES  NO   
 
